中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Glycyrrhetinic acid loaded in milk-derived extracellular vesicles for inhalation therapy of idiopathic pulmonary fibrosis

文献类型：期刊论文

作者Ran, Bo2,5,6; Ren, Xiaohong4,5; Lin, Xueyuan2,5,6; Teng, Yupu2,5,6; Xin, Fangyuan2,5,6; Ma, Wuzhen3,5; Zhao, Xiangyu2,5; Li, Mingwei2,5; Wang, Jinghuang2,5,6; Wang, Caifen5,6
刊名JOURNAL OF CONTROLLED RELEASE
出版日期2024-06-01
卷号370页码:811-820
关键词Idiopathic pulmonary fibrosis Glycyrrhizic acid Pifenidone Milk-derived extracellular vesicles Inhalation administration
ISSN号0168-3659
DOI10.1016/j.jconrel.2024.05.024
通讯作者Sun, Lixin(slx04@163.com) ; Zhang, Jiwen(jwzhang@simm.ac.cn)
英文摘要Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and life-threatening lung disease for which treatment options are limited. Glycyrrhetinic acid (GA) is a triterpenoid with multiple biological effects, such as antiinflammatory and anti-fibrotic properties. Herein, inhalable milk-derived extracellular vesicles (mEVs) encapsulating GA (mEVs@GA) were screened and evaluated for IPF treatment. The results indicated that the loading efficiency of GA in mEVs@GA was 8.65%. Therapeutic effects of inhalable mEVs@GA were investigated in vitro and in vivo. The mEVs@GA demonstrated superior anti-inflammatory effects on LPS-stimulated MHS cells. Furthermore, repeated noninvasive inhalation delivery of mEVs@GA in bleomycin-induced IPF mice could decrease the levels of transforming growth factors beta 1 (TGF-beta 1), Smad3 and inflammatory cytokines IL-6, IL-1 beta and TNF-alpha. The mEVs@GA effectively diminished the development of fibrosis and improved pulmonary function in the IPF mice model at a quarter of the dose compared with the pirfenidone oral administration group. Additionally, compared to pirfenidone-loaded mEVs, mEVs@GA demonstrated superior efficacy at the same drug concentration in the pharmacodynamic study. Overall, inhaled mEVs@GA have the potential to serve as an effective therapeutic option in the treatment of IPF.
WOS关键词EXOSOMES
资助项目National Science and Technology Major Projects for National Key Research and Development Program of China[2020YFE0201700]
WOS研究方向Chemistry ; Pharmacology & Pharmacy
语种英语
WOS记录号WOS:001243375500001
出版者ELSEVIER
源URL[http://119.78.100.183/handle/2S10ELR8/311416]  
专题中国科学院上海药物研究所
通讯作者Sun, Lixin; Zhang, Jiwen
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201210, Peoples R China
2.Yangtze Delta Drug Adv Res Inst, Nantong 226126, Peoples R China
3.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
4.Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau 999078, Peoples R China
5.Chinese Acad Sci, Ctr Drug Delivery Syst, Shanghai Inst Mat Med, Shanghai 201210, Peoples R China
6.Shenyang Pharmaceut Univ, Shenyang 110016, Peoples R China
推荐引用方式
GB/T 7714		 Ran, Bo,Ren, Xiaohong,Lin, Xueyuan,et al. Glycyrrhetinic acid loaded in milk-derived extracellular vesicles for inhalation therapy of idiopathic pulmonary fibrosis[J]. JOURNAL OF CONTROLLED RELEASE,2024,370:811-820.
APA Ran, Bo.,Ren, Xiaohong.,Lin, Xueyuan.,Teng, Yupu.,Xin, Fangyuan.,...&Zhang, Jiwen.(2024).Glycyrrhetinic acid loaded in milk-derived extracellular vesicles for inhalation therapy of idiopathic pulmonary fibrosis.JOURNAL OF CONTROLLED RELEASE,370,811-820.
MLA Ran, Bo,et al."Glycyrrhetinic acid loaded in milk-derived extracellular vesicles for inhalation therapy of idiopathic pulmonary fibrosis".JOURNAL OF CONTROLLED RELEASE 370(2024):811-820.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。